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Neutrophils are the most abundant white blood cells and are the first recruited to 
inflammatory sites. Neutrophils are an important component of the tumor stroma and 
can exert both anti-tumoral and pro-tumoral activities, depending on their maturation 
and activation state. In human gliomas, the number of circulating and infiltrating neu-
trophils correlates with the severity of the disease, indicating a prognostic and possible 
pro-tumoral role for these leukocytes. In glioma preclinical models, neutrophils promote 
tumor growth and orchestrate the resistance to anti-angiogenic therapies. Nevertheless, 
recent data indicate that neutrophils can be activated to directly kill tumor cells or to 
orchestrate the anti-tumoral response. Here, we review current knowledge about the 
role of neutrophils in glioma and their possible involvement in new strategies to improve 
current cancer therapies.
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inTRODUCTiOn
Gliomas represent approximately 80% of malignant brain tumors with an estimated annual inci-
dence of 6.6 per 100,000 individuals in the USA. Before publication of the revised World Health 
Organization (WHO) Classification of Tumors of the central nervous system (CNS) in 2016, gliomas 
were historically classified into four major histological groups (grades I–IV), according to their 
microscopic characteristics (such as cytological atypia, anaplasia, mitotic activity, microvascular 
proliferation, and necrosis) and clinical behavior. These tumors were also divided into astrocytomas 
(WHO grade I–IV), oligodendrogliomas (WHO grade II–III), and mixed oligoastrocytomas (WHO 
grade II–III) depending on their putative cells of origin.
Grade IV glioma or glioblastoma (GBM) is the most common and lethal primary brain tumor 
in adults and notoriously has a highly aggressive clinical course with a median survival time rang-
ing from 12.2 to 18.2 months and less than 5% of patients alive after 5-year from initial diagnosis. 
In contrast, gliomas of lower grade (WHO grade II–III), accounting for approximately one-third 
of all gliomas, are usually less aggressive tumors with a highly variable clinical course that is not 
adequately predicted on the basis of their histologic class. Some are indolent tumors, but others 
quickly progress to a more aggressive form or to GBM over years. Genome-wide molecular-profiling 
studies have now revealed a comprehensive mutational landscape for all major types of human glio-
mas occurring in adults and in children (1). In the revised 2016 WHO Classification of Tumors of the 
CNS, the advances in our molecular understanding of gliomas are integrated in a novel, multilayered 
approach to disease categorization that incorporates both histological and molecular information to 
better define many tumor entities and their prognosis.
Despite all these molecular efforts, the current standard of care for newly diagnosed GBM 
has remained unchanged over the past 10  years and includes maximal safe resection followed 
by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide (2). Current 
feasible therapeutic options for lower-grade gliomas vary with the extent of resection, histologic 
class, grade, and the results of molecular testing (IDH mutations and 1p and 19q co-deletion) 
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and include clinical monitoring, radiation alone, sequential, 
or concomitant chemo-radiation. Outcome for patients with 
recurrent/progressive disease is dismal, and no therapeutic 
intervention has been associated with durable survival benefit. 
According to that, considerable interest has been directed in the 
development of more effective therapies including innovative 
therapeutic approaches.
However, clinical trials evaluating intensifying cytotoxic 
therapy, targeting dysregulated cell signaling pathways (3), and 
blocking angiogenesis (4) failed to prolong patients’ survival. 
Giving the exciting and durable clinical benefits achieved for a 
number of other challenging cancers, recent efforts have been 
directed toward the modulation of the immune system by various 
therapeutic interventions also in the neuro-oncology field. Until 
now immunotherapeutic strategies for gliomas were only partially 
successful, further underlying the strong immunosuppressive 
potential of these tumors (5). This article aims to review the role 
of neutrophils in glioma, their role in the immunosuppression, 
and resistance to therapies and possible strategies to harness their 
anti-tumoral potential to fight gliomas.
THe iMMUne ReSPOnSe in THe CnS
The CNS has traditionally been recognized as an immune-
privileged site lacking the potential for immunosurveillance 
due to the presence of the blood–brain barrier (BBB) and the 
absence of a conventional lymphatic system. Lack of immune 
response is provided by preclinical data demonstrating the pro-
longed survival of tissues grafted into brain that were otherwise 
rejected rapidly by the immune system when grown outside the 
CNS. However, this paradigm has been recently challenged and 
it is becoming increasingly clear that the CNS interacts dynami-
cally with the systemic immune system. Recent data indicate 
that leukocytes can traffic to the CNS, even in the presence of an 
intact BBB, and that CNS antigens can reach peripheral lymph 
nodes by draining cerebrospinal fluid (CSF) through Virchow-
Robin spaces (6, 7). Furthermore, in 2015, the presence of 
lymphatic vessels within the dural sinuses capable of shuttling 
leukocytes between CSF and deep cervical lymphatic vessels has 
been reported (8).
In homeostatic conditions, leukocytes are only present in 
the CSF and in the vessels and they do not enter in the brain 
parenchima. The only immune cells that are present in the CNS 
are parenchymal macrophages (microglia) that have a prenatal 
origin, are long-lived, and have no turnover with blood mono-
cytes (9). Furthermore, in the brain, there are nonparenchymal 
macrophages named perivascular, meningeal, and choroid plexus 
macrophages that are strategically located at the CNS barrier and 
are thought to modulate leukocyte traffic and to sense blood 
danger signals (9).
Naive T cells do not readily enter the normal or inflamed CNS. 
Rather, T cells need to be highly activated to enter the brain, sug-
gesting that they need to be primed in the periphery to be able 
to enter to this site (10). Inflammatory monocytes infiltrate the 
brain during autoimmune and neurodegenerative diseases with 
an intact BBB, indicating that they are actively recruited to the 
CNS. The CCR2/CCL2 axis seems to be crucial for the trafficking 
of monocytes across the BBB (11). Neutrophils can infiltrate the 
brain with a LFA-1-dependent mechanism during Alzheimer 
disease (12), and in a murine model of sepsis, neutrophils are 
actively recruited to the brain by the chemokines, such as CXCL1, 
CXCL2, and CXCL3 (13). In has to be noted that in humans the 
chemokines involved in brain recruitment of neutrophils can be 
different because mice do not express CXCL8 the major human 
neutrophil attractant.
THe ROLe OF THe iMMUne SYSTeM in 
GLiOMA
By interfering with different aspects of tumor growth and 
responsiveness to therapy, the interplay between tumor cells 
and the immune system is emerging as a key modulator of 
tumor biology and one of the major determinants of cancer 
pathogenesis and progression (14). Increasing evidence indi-
cates that tumors develop and progress by co-opting seemingly 
normal host cell types that reside in or are recruited to tumor 
microenvironment.
In glioma patients, there is a profound and generalized immu-
nosuppression, particularly within the context of cell-mediated 
immunity (Figure  1). The systemic immunosuppression is 
driven by overexpression by the glioma cells of soluble factors, 
such as prostaglandin E2, TGF-β, indoleamine 2,3-dioxygenase, 
and IL-10, all of which lead to decrease T-cell responsiveness to 
pro-inflammatory signals and ineffective presentation of tumor 
antigens by antigen-presenting cells (APCs). On the other side, 
the same mediators drive the recruitment of immunosuppressive 
cells, such as regulatory T  cells and myeloid suppressor cells, 
to the tumor microenvironment. Moreover, corticosteroids 
(often used in glioma patients to diminish cerebral edema) 
are immunosuppressive, and temozolomide chemotherapy 
and radiotherapy can trigger prolonged lymphopenia. Several 
immunosuppressive alterations do occur within the glioma 
microenvironment. Glioma cells can down-regulate their own 
MHC-I complexes, thus becoming “invisible” to the adaptive 
immune system, as well as increase expression of immune check-
point regulators, such as PD-1 (15–17). Specific blockade of PD-1 
in combination with radiotherapy induced tumor regression 
and promoted long-term survival in animal models of glioma 
(18). The combination therapy of anti-CTLA-4 and anti-PD-1 
has resulted in a 75% long-term remission in an orthotopic, 
immunocompetent murine GBM model. In this model, there 
were increased numbers of activated CD8+ and NK  cells with 
reductions in suppressive immune cells in the tumor microen-
vironment (19). Additionally, combined blockade of CTLA-4, 
PD-1 and indoleamine dioxygenase, and anti-CTLA-4 therapy 
alone have resulted in long-term survival in other murine mod-
els of GBM and combined blockade of CTLA-4 and IL-12 was 
shown to increase numbers of effector T cells and decrease Tregs 
(20–22).
Multiple strategies to overcome immunosuppression and 
boost anti-tumor immune responses are now under evaluation 
in clinical trials, including vaccination with tumor-specific or 
tumor-associated peptides (or with administration of autologous 
FiGURe 1 | The immune response in gliomas. Glioma cells overexpress TGF-β and IL-10, immunosuppressive cytokines that decrease T-cell responsiveness and 
antigen-presenting cell function. Glioma cells down-regulate MHC-I and upregulate programmed death ligand-1 (PD-L1) expression leading to defective T-cell 
responsiveness. TCR activity is also dampened through CTLA-4 expression. TGF-β and IL-10 promote the recruitment and differentiation of regulatory T cells. 
Finally, secretion of CSF-1 and GM-CSF by glioma cells increase macrophage recruitment and polarization to M2-like phenotype.
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APCs pulsed with such peptides), immunomodulatory monoclo-
nal antibodies that target T-cell inhibitory signaling pathways to 
enhance physiological anti-tumor responses and adoptive T-cell 
transfer, which involves ex vivo clonal expansion or genetic engi-
neering of T cells (23).
In addition to strategies aimed to T-cell activation, efforts 
were also done to target tumor-associated macrophages to inhibit 
glioma progression. Indeed, macrophages appear to be the main 
infiltrating immune cells in gliomas. Several approaches have 
been performed using inhibitors of the CSF-1 receptor (CD115). 
This treatment blocks maturation of monocytes and polarization 
of macrophages toward an M2-like pro-tumoral phenotype and 
resulted in increased survival of the GBM-bearing mice (24, 25). 
Other myeloid cells are present in the glioma microenviron-
ment, including neutrophils (26). These leukocytes, until a few 
years ago, were considered as innocent bystanders in the tumor 
stroma, and their role in the tumor context was not investigated. 
On the contrary, emerging evidence indicates that neutrophils 
can play an important role in tumors having both pro-tumoral 
and anti-tumoral functions.
neUTROPHiLS AnD CAnCeR
Neutrophils are the most abundant leukocyte population in the 
bloodstream, and they are essential effectors of the inflamma-
tory response and defense against pathogens. Even if neutro-
phils are mostly considered for their anti-microbial functions, 
it is now evident that they exert a broader role in the immune 
response (27).
In the cancer setting, neutrophils were considered for a 
long time only for their pro-tumoral activities because in many 
cancer types, neutrophilia and an elevated ratio of peripheral 
neutrophils-to-lymphocytes counts (NLR) are associated with 
poor prognosis (28, 29). They were considered the main cell type 
mediating immunosuppression and tumor promotion. Only 
recently their anti-tumoral potential has been reconsidered 
for several reasons. First, clinical studies have indicated that 
neutrophil infiltration is associated with a favorable prognosis 
in gastric cancer (30), in colorectal cancer (31), and in early 
stages of non-small-cell lung carcinoma (32). Second, preclini-
cal data have indicated that circulating and tumor-infiltrating 
neutrophils are not a homogeneous population as previously 
considered. Tumor-derived cytokines induce the appearance 
in the blood of immature neutrophils with immunosuppres-
sive activities (33) and neutrophils with an “aged” phenotype 
that are experienced cells with increased ability to respond to 
inflammatory stimuli that can have an anti-tumoral role (34). 
Also, in the tumor tissue, as macrophages, neutrophils are pre-
sent in different polarized states: N1 anti-tumoral phenotype 
induced by IFN-β stimulation and N2 pro-tumoral phenotype 
induced by TGF-β and G-CSF stimulation (35). In addition, 
several preclinical data have indicated that neutrophils can 
be activated to kill tumor cells. Neutrophils mediate the 
therapeutic effect of monoclonal antibodies such as rituximab 
and trastuzumab in breast cancer (36) and lymphoma (37, 38) 
through antibody-dependent cellular cytotoxicity (ADCC). 
Neutrophils are the effector cells in the regression of Fas ligand 
(FasL)-expressing tumors through the expression of Fas (39). 
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They also mediate the anti-tumor activity of the PKC modulator 
ingenol-3-angelate (PEP005) in skin tumors. PEP005 induces 
the recruitment and the activation of neutrophils that kill the 
tumor cells by ADCC (40). Neutrophils are again the effec-
tor cells in Bacillus Calmette–Guérin-based bladder tumor 
immunotherapy inducing death of cancer cells by release of 
TRAIL (41). Interestingly, reactive oxygen species production 
by neutrophils mediates the immune-mediated abscopal effect 
of radiotherapy that is tumor regression outside the radiation 
field (42). Finally, neutrophils are mediating the anti-tumoral 
activity of the tyrosine kinase inhibitor Cabozantinib in pros-
tate cancer models. Cabozantinib induces the production of 
neutrophil chemotactic factors such as CXCL12 and HMGB1 
that promote a strong infiltration and activation of neutrophils 
that kill tumor cells (43).
neUTROPHiLS AnD GLiOMA
As for other cancer patients, most of the glioma patients have a 
strong neutrophilia (44) due to overproduction by tumor cells 
of G-CSF, the growth factor for neutrophils (45, 46). G-CSF 
diverts BM hematopoiesis away from the lymphocyte lineage 
toward the granulocyte one and for this reason patients have 
a high NLR. NLR higher than 4 has been associated with poor 
prognosis when measured before treatments (47, 48), after the 
second surgery (49), and after temozolomide chemotherapy 
and radiotherapy (50). NLR less than 4 is associated to bet-
ter prognosis but only in GBM expressing the wild-type gene 
IDH1, one of the genes more frequently mutated in malignant 
gliomas (51). Activation of neutrophils, measured by increased 
surface expression of CD11b, is an early predictor of tumor 
progression in GBM patients (52). Circulating neutrophils 
promote tumor growth inducing immunosuppression by pro-
duction of arginase I (53). Interestingly, baseline neutrophil 
count in blood predicts bevacizumab efficacy in GBM patients. 
However, neutrophils are not involved in the anti-tumor 
response but are, on the contrary, the target of the anti-VEGF-
A therapy being the main producers of this proangiogenic 
cytokine (54).
Neutrophils are also present within the tumor lesions (55), 
and there is a correlation between NLR and the degree of neu-
trophil infiltration (56). The number of infiltrating neutrophils 
is correlated with glioma grade and with acquired resistance to 
anti-VEGF therapy in GBM (55, 57). Clinical data suggest that 
neutrophils have a negative prognostic value in GBM patients, 
but the mechanism of their recruitment and their role in tumor 
growth are ill defined. In addition, preclinical studies have an 
important limitation due to differences in relative abundance of 
FiGURe 2 | Circulating and infiltrating neutrophils sustain glioma growth. (A) In glioma patients, high NLR is associated with poor prognosis. Neutrophil activation 
measured as increased CD11b level, is an early sign of tumor progression. Secretion of Arginase-1 by neutrophil promotes immunosuppression and VEGF-A 
production induces angiogenesis. (B) Glioma cells attract neutrophils by producing the chemoattractants CXCL8 and MIF. Tumor-associated neutrophils exert their 
pro-tumoral role expressing elastase that sustains glioma infiltration and S100A4 that increases tumor proliferation rate.
5Massara et al. The Role of Neutrophils in Glioma
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1349
ReFeRenCeS
1. Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, 
Kinnersley B, et  al. Genome-wide association study of glioma subtypes 
identifies specific differences in genetic susceptibility to glioblastoma 
and non-glioblastoma tumors. Nat Genet (2017) 49:789–94. doi:10.1038/
ng.3823 
2. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, 
et al. Effects of radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a randomised phase 
III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 
10:459–66. doi:10.1016/S1470-2045(09)70025-7 
3. Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, et  al. The challenges and the 
promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 
17:239–55. doi:10.1016/j.neo.2015.02.002 
4. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, 
et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. 
N Engl J Med (2014) 370:699–708. doi:10.1056/NEJMoa1308573 
5. Ampie L, Woolf EC, Dardis C. Immunotherapeutic advancements for glio-
blastoma. Front Oncol (2015) 5:12. doi:10.3389/fonc.2015.00012 
6. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, 
et  al. Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 
16:1441–58. doi:10.1093/neuonc/nou212 
7. Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune 
privilege of the CNS. Nat Immunol (2017) 18:123–31. doi:10.1038/ni.3666 
8. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et  al. 
Structural and functional features of central nervous system lymphatic vessels. 
Nature (2015) 523:337–41. doi:10.1038/nature14432 
9. Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady 
state and disease. Nat Neurosci (2017) 20:136–44. doi:10.1038/nn.4475 
10. Beena J, Hunter C, Harris TH. Immune cell trafficking in the central nervous 
system. In:  Peterson  MTP, editor. Neuroinflammation and Neurodegeneration. 
New York: Springer (2014). p. 29–45.
11. Harrison-Brown M, Liu GJ, Banati R. Checkpoints to the brain: directing 
myeloid cell migration to the central nervous system. Int J Mol Sci (2016) 17. 
doi:10.3390/ijms17122030 
12. Zenaro E, Pietronigro E, Della Bianca V, Piacentino G, Marongiu L, Budui S, 
et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive 
decline via LFA-1 integrin. Nat Med (2015) 21:880–6. doi:10.1038/nm.3913 
13. He H, Geng T, Chen P, Wang M, Hu J, Kang L, et al. NK cells promote neu-
trophil recruitment in the brain during sepsis-induced neuroinflammation. 
Sci Rep (2016) 6:27711. doi:10.1038/srep27711 
14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. 
Nature (2008) 454:436–44. doi:10.1038/nature07205 
15. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, et al. Downregulation 
of major histocompatibility complex antigens in invading glioma cells: 
stealth invasion of the brain. Lab Invest (2005) 85:328–41. doi:10.1038/
labinvest.3700233 
16. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et  al. 
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes 
in glioblastoma. Neuro Oncol (2015) 17:1064–75. doi:10.1093/neuonc/nou307 
17. Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-
L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2016) 
18:195–205. doi:10.1093/neuonc/nov172 
18. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 
blockade and stereotactic radiation produce long-term survival in mice 
with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 86:343–9. 
doi:10.1016/j.ijrobp.2012.12.025 
19. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, 
et al. Glioblastoma eradication following immune checkpoint blockade in an 
orthotopic, immunocompetent model. Cancer Immunol Res (2016) 4:124–35. 
doi:10.1158/2326-6066.CIR-15-0151 
20. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. 
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ 
T cell compartment without affecting regulatory T-cell function. Clin Cancer 
Res (2007) 13:2158–67. doi:10.1158/1078-0432.CCR-06-2070 
21. Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, 
et  al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell- 
mediated glioma rejection. J Exp Med (2013) 210:2803–11. doi:10.1084/
jem.20130678 
22. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, 
et  al. Durable therapeutic efficacy utilizing combinatorial blockade against 
neutrophils in the circulation between human and mice (50–70 
and 10–25%, respectively).
Neutrophils are recruited at tumor site by CXCL8 produced 
by FasL triggering on glioma cells (58, 59). Immunosuppressive 
neutrophils are also recruited by the chemotactic agent MIF 
produced by glioma cancer stem cells (60). At the tumor site, 
neutrophils secrete elastase that can aid glioma infiltration (61) 
and can directly induce the proliferation of GBM-initiating cells 
by producing S100A4 (57). Neutrophils are also contributing to 
the resistance to anti-angiogenic therapy (62). Consistently with 
their pro-tumoral role, depletion of neutrophils using the mono-
clonal antibody against Ly6G prolonged the survival of mice with 
developing gliomas (63). Moreover, mutant IDH1 glioma tumors 
that have a longer survival compared to wild-type IDH1 have a 
reduced neutrophil infiltration (64).
COnCLUSiOn AnD FUTURe 
PeRSPeCTiveS
To date, most studies performed on glioma patients suggest that 
neutrophilia and neutrophil infiltration at tumor site have a nega-
tive prognostic role in the survival and response to anti-angiogenic 
therapies (Figure 2). Therefore, most of the approaches are tar-
geted at inhibiting neutrophil migration to the tumor site. Because 
in other tumors, neutrophils can directly exert an important 
antineoplastic activity and improve the efficiency of current 
therapies, such as anti-cancer antibodies and checkpoint inhibi-
tors, it will be important to uncover this possibility also in glioma.
Consideration should be given to the possibility to improve 
monoclonal antibody therapies by combination with treat-
ments that promote the differentiation of neutrophils into an 
anti-tumor phenotype with higher ADCC activity. Interestingly, 
two treatments, type I IFNs (65) and TGF-β targeting (56), that 
can promote neutrophil differentiation toward an anti-tumoral 
phenotype are inducing glioma regression. Current therapies 
may also be combined with treatments that promote selective 
recruitment of anti-tumoral neutrophils at the tumor site (66). 
Finally, the ability of neutrophils to migrate in the inflamed brain 
can be exploited to deliver anti-cancer drugs in gliomas after 
surgery, reducing regrowth of tumors (67).
AUTHOR COnTRiBUTiOnS
All the authors have contributed to this review by writing and 
critically evaluating the literature.
FUnDinG
Research activities in the laboratory are supported by the Italian 
Association for Cancer Research, AIRC IG 2014—15438.
6Massara et al. The Role of Neutrophils in Glioma
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1349
IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res (2014) 
20:5290–301. doi:10.1158/1078-0432.CCR-14-0514 
23. Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation 
for glioblastoma. Curr Opin Neurol (2017) 30:361–9. doi:10.1097/WCO. 
0000000000000451 
24. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, 
et  al. CSF-1R inhibition alters macrophage polarization and blocks glioma 
progression. Nat Med (2013) 19:1264–72. doi:10.1038/nm.3337 
25. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. 
Cancer Cell (2017) 31:326–41. doi:10.1016/j.ccell.2017.02.009 
26. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in 
brain tumours. Acta Neuropathol (2014) 128:347–62. doi:10.1007/s00401- 
014-1274-2 
27. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nat Rev Immunol 
(2011) 11:519–31. doi:10.1038/nri3024 
28. Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-associated neutrophils 
as a new prognostic factor in cancer: a systematic review and meta-analysis. 
PLoS One (2014) 9:e98259. doi:10.1371/journal.pone.0098259 
29. Templeton AJ, Mcnamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, 
et  al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a 
systematic review and meta-analysis. J Natl Cancer Inst (2014) 106:dju124. 
doi:10.1093/jnci/dju124 
30. Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C. Prognostic 
value of intratumoral neutrophils in advanced gastric carcinoma in a high-
risk area in northern Italy. Mod Pathol (2002) 15:831–7. doi:10.1097/01.MP. 
0000020391.98998.6B 
31. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, 
et al. Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated 
with improved survival in patients with colorectal carcinoma. Int J Cancer 
(2011) 128:2663–72. doi:10.1002/ijc.25609 
32. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, 
Deshpande C, et al. Tumor-associated neutrophils stimulate T cell responses in 
early-stage human lung cancer. J Clin Invest (2014) 124:5466–80. doi:10.1172/
JCI77053 
33. Zhang D, Chen G, Manwani D, Mortha A, Xu C, Faith JJ, et al. Neutrophil age-
ing is regulated by the microbiome. Nature (2015) 525:528–32. doi:10.1038/
nature15367 
34. Adrover JM, Nicolas-Avila JA, Hidalgo A. Aging: a temporal dimension for 
neutrophils. Trends Immunol (2016) 37:334–45. doi:10.1016/j.it.2016.03.005 
35. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of 
tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. 
Cancer Cell (2009) 16:183–94. doi:10.1016/j.ccr.2009.06.017 
36. Stockmeyer B, Beyer T, Neuhuber W, Repp R, Kalden JR, Valerius T, et  al. 
Polymorphonuclear granulocytes induce antibody-dependent apoptosis 
in human breast cancer cells. J Immunol (2003) 171:5124–9. doi:10.4049/
jimmunol.171.10.5124 
37. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, 
et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 
(2013) 122:3160–4. doi:10.1182/blood-2013-04-497446 
38. Eruslanov EB, Singhal S, Albelda SM. Mouse versus human neutrophils in 
cancer: a major knowledge gap. Trends Cancer (2017) 3:149–60. doi:10.1016/j.
trecan.2016.12.006 
39. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally 
produced CD95 ligand. Nat Med (1997) 3:165–70. doi:10.1038/nm0297-165 
40. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, 
et  al. Neutrophils are a key component of the antitumor efficacy of topical 
chemotherapy with ingenol-3-angelate. J Immunol (2006) 177:8123–32. 
doi:10.4049/jimmunol.177.11.8123 
41. Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, 
et  al. Neutrophil granulocytes are required for effective Bacillus Calmette-
Guerin immunotherapy of bladder cancer and orchestrate local immune 
responses. Cancer Res (2006) 66:8250–7. doi:10.1158/0008-5472.CAN- 
06-1416 
42. Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R. Key role for 
neutrophils in radiation-induced antitumor immune responses: potentiation 
with G-CSF. Proc Natl Acad Sci U S A (2016) 113:11300–5. doi:10.1073/
pnas.1613187113 
43. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, 
Gehring MP, et al. Cabozantinib eradicates advanced murine prostate cancer 
by activating anti-tumor innate immunity. Cancer Discov (2017) 7:750–65. 
doi:10.1158/2159-8290.CD-16-0778 
44. Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, 
et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage 
phenotype. JCI Insight (2016) 1. doi:10.1172/jci.insight.85841 
45. Nitta T, Sato K, Allegretta M, Brocke S, Lim M, Mitchell DJ, et al. Expression 
of granulocyte colony stimulating factor and granulocyte-macrophage colony 
stimulating factor genes in human astrocytoma cell lines and in glioma 
specimens. Brain Res (1992) 571:19–25. doi:10.1016/0006-8993(92)90505-4 
46. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, et al. 
Cytokine patterns in brain tumour progression. Mediators Inflamm (2013) 
2013:979748. doi:10.1155/2013/979748 
47. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, et al. The 
association of pre-treatment neutrophil to lymphocyte ratio with overall 
survival in patients with glioblastoma multiforme. J Neurooncol (2013) 
114:149–54. doi:10.1007/s11060-013-1164-9 
48. Wiencke JK, Koestler DC, Salas LA, Wiemels JL, Roy RP, Hansen HM, et al. 
Immunomethylomic approach to explore the blood neutrophil lymphocyte 
ratio (NLR) in glioma survival. Clin Epigenetics (2017) 9:10. doi:10.1186/
s13148-017-0316-8 
49. McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Bernstein M, et al. 
Factors impacting survival following second surgery in patients with glio-
blastoma in the temozolomide treatment era, incorporating neutrophil/lym-
phocyte ratio and time to first progression. J Neurooncol (2014) 117:147–52. 
doi:10.1007/s11060-014-1366-9 
50. Mason M, Maurice C, Mcnamara MG, Tieu MT, Lwin Z, Millar BA, 
et  al. Neutrophil-lymphocyte ratio dynamics during concurrent chemo- 
radiotherapy for glioblastoma is an independent predictor for overall survival. 
J Neurooncol (2017) 132:463–71. doi:10.1007/s11060-017-2395-y 
51. Wang PF, Song HW, Cai HQ, Kong LW, Yao K, Jiang T, et  al. Preoperative 
inflammation markers and IDH mutation status predict glioblastoma patient 
survival. Oncotarget (2017) 8:50117–23. doi:10.18632/oncotarget.15235 
52. Rahbar A, Cederarv M, Wolmer-Solberg N, Tammik C, Stragliotto G, Peredo I, 
et al. Enhanced neutrophil activity is associated with shorter time to tumor 
progression in glioblastoma patients. Oncoimmunology (2016) 5:e1075693. 
doi:10.1080/2162402X.2015.1075693 
53. Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-Demasters BK, 
et  al. Neutrophil degranulation and immunosuppression in patients with 
GBM: restoration of cellular immune function by targeting arginase I. Clin 
Cancer Res (2011) 17:6992–7002. doi:10.1158/1078-0432.CCR-11-1107 
54. Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangere V, Vincent J, 
et  al. Blood baseline neutrophil count predicts bevacizumab efficacy in 
glioblastoma. Oncotarget (2016) 7:70948–58. doi:10.18632/oncotarget.10898 
55. Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil 
infiltration into human gliomas. Acta Neuropathol (1999) 98:349–54. 
doi:10.1007/s004010051093 
56. Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lympho-
cyte ratio is associated with neutrophil and T-cell infiltration and predicts 
clinical outcome in patients with glioblastoma. BMC Cancer (2015) 15:617. 
doi:10.1186/s12885-015-1629-7 
57. Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, et  al. Neutrophils 
promote the malignant glioma phenotype through S100A4. Clin Cancer Res 
(2014) 20:187–98. doi:10.1158/1078-0432.CCR-13-1279 
58. Chio CC, Wang YS, Chen YL, Lin SJ, Yang BC. Down-regulation of Fas-L 
in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, 
and liver damage but accelerates tumour formation in nude mice. Br J Cancer 
(2001) 85:1185–92. doi:10.1054/bjoc.2001.2055 
59. Hor WS, Huang WL, Lin YS, Yang BC. Cross-talk between tumor cells and 
neutrophils through the Fas (APO-1, CD95)/FasL system: human glioma 
cells enhance cell viability and stimulate cytokine production in neutrophils. 
J Leukoc Biol (2003) 73:363–8. doi:10.1189/jlb.0702375 
60. Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, 
Sorensen MD, et  al. Cancer stem cell-secreted macrophage migration 
inhibitory factor stimulates myeloid derived suppressor cell function and 
facilitates glioblastoma immune evasion. Stem Cells (2016) 34:2026–39. 
doi:10.1002/stem.2393 
7Massara et al. The Role of Neutrophils in Glioma
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1349
61. Iwatsuki K, Kumara E, Yoshimine T, Nakagawa H, Sato M, Hayakawa T. 
Elastase expression by infiltrating neutrophils in gliomas. Neurol Res (2000) 
22:465–8. doi:10.1080/01616412.2000.11740701 
62. Achyut BR, Shankar A, Iskander AS, Ara R, Angara K, Zeng P, et al. Bone 
marrow derived myeloid cells orchestrate antiangiogenic resistance in 
glioblastoma through coordinated molecular networks. Cancer Lett (2015) 
369:416–26. doi:10.1016/j.canlet.2015.09.004 
63. Fujita M, Scheurer ME, Decker SA, Mcdonald HA, Kohanbash G, Kastenhuber ER, 
et al. Role of type 1 IFNs in antiglioma immunosurveillance – using mouse 
studies to guide examination of novel prognostic markers in humans. Clin 
Cancer Res (2010) 16:3409–19. doi:10.1158/1078-0432.CCR-10-0644 
64. Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, et al. Mutant 
IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 
(2017) 31:774–86. doi:10.1101/gad.294991.116 
65. Galani V, Papadatos SS, Alexiou G, Galani A, Kyritsis AP. In vitro and in vivo 
preclinical effects of type I IFNs on gliomas. J Interferon Cytokine Res (2017) 
37:139–46. doi:10.1089/jir.2016.0094 
66. Bonavita O, Massara M, Bonecchi R. Chemokine regulation of neutrophil 
function in tumors. Cytokine Growth Factor Rev (2016) 30:81–6. doi:10.1016/j.
cytogfr.2016.03.012 
67. Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y, et al. Neutrophil-mediated 
anticancer drug delivery for suppression of postoperative malignant glioma 
recurrence. Nat Nanotechnol (2017) 12:692–700. doi:10.1038/nnano.2017.54 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Massara, Persico, Bonavita, Mollica Poeta, Locati, Simonelli and 
Bonecchi. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in other 
forums is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these terms.
